Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Hong Kong Special Administrative Region, The People's Republic of China.
Ophthalmology. 2010 Mar;117(3):471-6. doi: 10.1016/j.ophtha.2009.08.016. Epub 2010 Jan 4.
To investigate whether simvastatin use is associated with visual field (VF) stabilization in patients with normal tension glaucoma (NTG).
Prospective cohort study (ClinicalTrials.gov Identifier: NCT00321386).
A total of 256 eyes from 256 Chinese subjects with NTG.
Patients were followed up at 4-month intervals for 36 months for VF progression per Anderson's criteria. Clinical parameters were checked for association with progression in multivariate analysis.
The primary outcome was the association between simvastatin use and VF progression.
Thirty-one patients (12.1%) were taking simvastatin (statin+), and 225 patients (87.9%) were not taking simvastatin (statin-). Baseline age, gender, untreated intraocular pressure, VF indices, vertical cup-to-disc ratio, and central corneal thickness (CCT) were comparable between the 2 groups. There were significantly more patients with a history of hypercholesterolemia, systemic hypertension, and ischemic heart disease in the statin+ group. A total of 121 patients (47.3%) showed evidence of VF progression (mean rate of mean deviation loss was -0.30 decibel per year) during the 36 months of follow-up. Simvastatin use was among 8 of 121 patients (6.6%) who progressed compared with 23 of 135 patients (17.0%) who did not progress (P = 0.011). Logistic regression revealed that history of disc hemorrhage (relative risk [RR] 3.26; 95% confidence interval [CI], 1.21-8.76; P = 0.019), history of cerebrovascular accidents (RR 2.28; 95% CI, 1.03-5.06; P = 0.043), and baseline age (per 10 years older; RR 1.38; 95% CI, 1.08-1.76; P = 0.009) were significant risk factors for VF progression, whereas simvastatin use conferred a protective effect (RR 0.36; 95% CI, 0.14-0.91; P = 0.030).
Simvastatin use may be associated with VF stabilization in patients with NTG. A larger scale randomized controlled trial and cost-effectiveness analyses seem warranted.
研究辛伐他汀的使用是否与正常眼压性青光眼(NTG)患者的视野(VF)稳定有关。
前瞻性队列研究(ClinicalTrials.gov 标识符:NCT00321386)。
256 名中国 NTG 患者的 256 只眼睛。
根据 Anderson 标准,每 4 个月对患者进行一次随访,以确定 VF 进展情况。在多变量分析中检查临床参数与进展的关系。
主要结局是辛伐他汀的使用与 VF 进展之间的关系。
31 名患者(12.1%)正在服用辛伐他汀(他汀组),225 名患者(87.9%)未服用辛伐他汀(他汀组)。两组患者的基线年龄、性别、未治疗的眼内压、VF 指数、垂直杯盘比和中央角膜厚度(CCT)相似。他汀组中有更多的患者有高胆固醇血症、系统性高血压和缺血性心脏病病史。在 36 个月的随访中,共有 121 名患者(47.3%)出现 VF 进展的证据(平均每年平均偏差损失率为-0.30 分贝)。在进展的 121 名患者中,有 8 名(6.6%)正在服用辛伐他汀,而在未进展的 135 名患者中有 23 名(17.0%)正在服用辛伐他汀(P = 0.011)。逻辑回归显示,视盘出血史(相对风险 [RR] 3.26;95%置信区间 [CI],1.21-8.76;P = 0.019)、脑血管意外史(RR 2.28;95% CI,1.03-5.06;P = 0.043)和基线年龄(每增加 10 岁;RR 1.38;95% CI,1.08-1.76;P = 0.009)是 VF 进展的显著危险因素,而辛伐他汀的使用则具有保护作用(RR 0.36;95% CI,0.14-0.91;P = 0.030)。
辛伐他汀的使用可能与 NTG 患者的 VF 稳定有关。似乎需要更大规模的随机对照试验和成本效益分析。